ESTRO 2024 - Abstract Book

S874

Clinical - CNS

ESTRO 2024

Astradsson A, Munck Af Rosenschöld P, Feldt-Rasmussen U, Poulsgaard L, Wiencke AK, Ohlhues L, Engelholm SA, Broholm H, Hansen Møller E, Klose M, Roed H, Juhler M. Visual outcome, endocrine function and tumor control after fractionated stereotactic radiation therapy of craniopharyngiomas in adults: findings in a prospective cohort. Acta Oncol. 2017 Mar;56(3):415-421. doi:10.1080/0284186X.2016.1270466. Epub 2017 Jan 13. PMID: 28084862. Khriguian J, Tolba M, Khosrow-Khavar F, Kordlouie S, Guiot MC, Abdulkarim B, Shenouda G, Sirhan D, Souhami L, Panet-Raymond V. Is Postoperative Radiotherapy Needed in the Management of Adult Craniopharyngiomas? Can J Neurol Sci. 2023 May;50(3):428-434. doi: 10.1017/cjn.2022.28. Epub 2022 May 18. PMID: 35581927.

1915

Proffered Paper

PET vs. MRI based reirradiation in glioblastoma. A prospective randomized trial (GLIAA, NCT01252459)

Anca Ligia Grosu 1,2 , Wolfgang A. Weber 3 , Erika Graf 4 , Michael Mix 5 , Rolf Wiehle 1 , Ursula Nestle 1 , Tanja Schimek Jasch 1 , Maximilian Niyazi 6 , Claus Belka 6 , Frank Paulsen 7 , Franziska Eckert 7 , Michael J. Eble 8 , Liane König 8 , Frank Anton Giordano 9 , Elena Sperk 9 , Felix Momm 10 , Irina Spehl 10 , Stephanie E. Combs 11 , Denise Bernhardt 11 , Rita Engenhart Cabillic 12 , Markus Michael Schymalla 12 , Martin Stuschke 13 , Christoph Pöttgen 13 , Rainer Fietkau 14 , Ilinca Popp 1,15 1 Medical Center - University of Freiburg, Faculty of Medicine, Department of Radiation Oncology, Freiburg, Germany. 2 German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Freiburg, Heidelberg, Germany. 3 School of Medicine, Technical University Munich, Department of Nuclear Medicine, Munich, Germany. 4 Medical Center-University of Freiburg, Faculty of Medicine, Institute of Medical Biometry and Statistics, Freiburg, Germany. 5 Medical Center - University of Freiburg, Faculty of Medicine, Department of Nuclear Medicine, Freiburg, Germany. 6 University Hospital, LMU Munich, Department of Radiation Oncology, Munich, Germany. 7 University Hospital Tübingen, University of Tübingen, Department of Radiation Oncology, Tübingen, Germany. 8 RWTH Aachen University, Department of Radiation Oncology, Aachen, Germany. 9 Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Department of Radiation Oncology, Mannheim, Germany. 10 Ortenau Klinikum Offenburg-Kehl, Academic Teaching Hospital of the Albert Ludwig University of Freiburg, Department of Radiation Oncology, Offenburg, Germany. 11 Klinikum Rechts der Isar, Technical University of Munich (TUM), Department of Radiation Oncology, Munich, Germany. 12 Philipps University Marburg, Department of Radiotherapy and Radio Oncology, Marburg, Germany. 13 West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, Department of Radiation Therapy, Essen, Germany. 14 Universitätsklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Department of Radiation Oncology, Erlangen, Germany. 15 On behalf of, GLIAA Study Group, Freiburg, Germany

Purpose/Objective:

The aim of this trial was to analyze whether a radiotherapy target volume delineation based on O-(2- [18F]fluoroethyl)-L-tyrosine (FET) positron emission tomography (PET) leads to an improvement in outcome for patients with recurrent glioblastoma (rGBM) treated with re-irradiation, as compared to a target volume delineation based on contrast enhanced T1-weighted magnetic resonance imaging (T1Gd-MRI).